Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
80 hedge funds and large institutions have $522M invested in Y-mAbs Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 10 closing their positions.
1.64% more ownership
Funds ownership: 48.84% → 50.48% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
1% less funds holding
Funds holding: 81 → 80 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
14% less capital invested
Capital invested by funds: $606M → $522M (-$83.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$15.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.35M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$4.7M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$3.95M |
| 5 |
Aviva
London,
United Kingdom
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.11M |
| 2 |
Morgan Stanley
New York
|
-$7.02M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$4.33M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.94M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.1M |
YMAB Hedge Fund Activity: Q1 2020 in Review
80 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2020, worth a combined $522M — down 14% from $606M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of YMAB and 9 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 30 added.
The largest buyer was Artisan Partners, opening a new position worth an estimated $15.9M. The largest seller was Millennium Management, cutting an estimated $7.11M.
- 80 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2020, down from 81 in Q4 2019.
- Funds reported $522M of Y-mAbs Therapeutics stock for Q1 2020, down 14% quarter-over-quarter.
- 9 funds opened new Y-mAbs Therapeutics positions in Q1 2020 and 10 closed out, a net change of -1 holder.
- The largest Y-mAbs Therapeutics buyer in Q1 2020 was Artisan Partners, an estimated $15.9M added.
- The largest Y-mAbs Therapeutics seller in Q1 2020 was Millennium Management, an estimated $7.11M sold.
Based on aggregated 13F filings for Q1 2020.